US LNG exports surge but will buyers in China turn up?
Charles Mosseri Marlio, a significant stakeholder in Nuvectis Pharma , Inc. (NASDAQ:NVCT), has increased his holdings in the company with a series of purchases totaling approximately $247,263. These transactions, which occurred on May 8 and May 9, 2025, involved the acquisition of common stock at prices ranging from $8.71 to $8.99 per share. The purchase prices align closely with the current trading price of $8.64, with InvestingPro data showing analyst price targets ranging from $15 to $25. Following these purchases, Mosseri Marlio’s total ownership, held indirectly through Emerald Hill Ventures SARL SPF, reached 2,936,594 shares. This series of acquisitions reflects an ongoing confidence in Nuvectis Pharma’s future performance, which appears well-founded given the company’s strong YTD return of 66% and robust liquidity position with a current ratio of 3.28. InvestingPro analysis reveals 8 additional key insights about NVCT’s financial health and growth prospects.
In other recent news, Nuvectis Pharma has reported promising results for their drug candidate, NXP900, in combination with osimertinib for treating non-small cell lung cancer (NSCLC) with specific mutations. Conducted at the Lerner Research Institute of the Cleveland Clinic, the study showed that this combination therapy was more effective than osimertinib alone, potentially decreasing cancer cell proliferation and increasing cell death. As the Phase 1a dose escalation study of NXP900 nears completion, Nuvectis is preparing to initiate the Phase 1b program. Additionally, the company’s other drug candidate, NXP800, is undergoing clinical trials for platinum-resistant ovarian carcinoma and cholangiocarcinoma.
Laidlaw analysts have initiated coverage of Nuvectis Pharma with a Buy rating and set a 12-month price target of $19.00, citing the company’s innovative approach in developing oncology treatments. The analysts highlighted Nuvectis Pharma’s focus on creating first-in-class therapies that could significantly impact the oncology field. The company’s strategic direction and the potential clinical applications of its lead product, NXP900, contribute to the positive sentiment from Laidlaw. As Nuvectis advances its product pipeline, the market will closely monitor further developments and clinical trial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.